▲ +25.69% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Nkarta in the last 3 months. The average price target is $59.00, with a high forecast of $81.00 and a low forecast of $41.00. The average price target represents a 25.69% upside from the last price of $46.94.
The current consensus among 4 polled investment analysts is to buy stock in Nkarta.
Nkarta, Inc., a biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its co-lead product candidates are NKX101, a pre-clinical product that enhances the power of innate NK biology to detect and kill cancerous cells; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company was founded in 2015 and is headquartered in South San Francisco, California.